US23306J2006 - ADR
DBV TECHNOLOGIES SA-SPON ADR
NASDAQ:DBVT (12/20/2024, 8:04:52 PM)
Premarket: 3.21 +0.02 (+0.63%)3.19
+0.14 (+4.59%)
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 106 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
DBV TECHNOLOGIES SA-SPON ADR
Batiment IRO, 107 Av. de la Republique
Chatillon AUVERGNE-RHONE-ALPES 92120
P: 33155427878
CEO: Daniel Tasse
Employees: 106
Website: https://www.dbv-technologies.com/
Stay updated with the stocks that are on the move in today's after-hours session.
Thursday's session: gap up and gap down stocks
Top movers in Wednesday's after hours session
Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 –...
Châtillon, France, le 11 décembre (22 :05 CEST) 2024 DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch...
Here you can normally see the latest stock twits on DBVT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: